EXD1

Across TCGA pan-cancer cohorts, EXD1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EXD1 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher EXD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EXD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KICH, ACC, and GBM are the cancer types where EXD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.025	0.904	<.001	36	view →
ACC	OS	Median	All	0.214	0.802	.002	15	view →
GBM	OS	Median	All	0.069	0.415	<.001	12	view →
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
BLCA	DFS	Median	III,IV	0.109	0.575	<.001	6	view →
UCEC	DFS	Median	All	0.959	0.620	.018	6	view →
COAD	OS	Median	All	0.168	0.805	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EXD1–KICH (DFS)

Open the KICH breakdown →